ILARIS

This brand name is authorized in Austria, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug ILARIS contains one active pharmaceutical ingredient (API):

1 Canacinumab
UNII 37CQ2C7X93 - CANAKINUMAB

Canacinumab is a human monoclonal anti-human interleukin-1 beta (IL-1 beta) antibody of the IgG1/κ isotype. Canacinumab binds with high affinity specifically to human IL-1 beta and neutralises the biological activity of human IL-1 beta by blocking its interaction with IL-1 receptors, thereby preventing IL-1 beta-induced gene activation and the production of inflammatory mediators.

Read about Canacinumab

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
Ilaris 150mg powder for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ILARIS Powder for solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L04AC08 Canacinumab L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 526517110091803, 526532001155318
Country: CA Health Products and Food Branch Identifier(s): 02460351
Country: EE Ravimiamet Identifier(s): 1439894, 1439906, 1540268, 1741430
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 109564004
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 444260
Country: FR Base de données publique des médicaments Identifier(s): 69541570
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 350356
Country: HK Department of Health Drug Office Identifier(s): 59736, 65635
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 8415
Country: JP 医薬品医療機器総合機構 Identifier(s): 3999434A1026
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1051079, 1051080, 1063298, 1082469
Country: NL Z-Index G-Standaard, PRK Identifier(s): 142794
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 14540
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100278666, 100388900
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W67327001, W67341001
Country: SG Health Sciences Authority Identifier(s): 13866P
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699504270051, 8699504270075
Country: US FDA, National Drug Code Identifier(s): 0078-0734
Country: ZA Health Products Regulatory Authority Identifier(s): 44/30.1/0097

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.